16 completed, 7 unknown, 3 recruiting, 3 withdrawn. 20 Phase 2, 12 Phase 1, 2 Phase 3, 1 Early Phase 1.
Follow pamiparib: new trials by email Literature Review of pamiparib trials Research Report on pamiparib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine - Rare Tumour | Phase 2 | Not yet recruiting | Peking University Shenzhen Hospital | 200 | 2025-01-01 | 2024-11-18 |
| Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) Rezvilutamide, Goserelin Microspheres for Injection, Docetaxel - Locally Advanced Prostate Cancer, Oligometastatic Prostate Cancer | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 40 | 2024-04-01 | 2024-04-26 |
| Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer Chemoradiation, Pamiparib, Hydroxyurea - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | University of Chicago | 30 | 2023-03-07 | 2026-03-04 |
| Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy Pamiparib/Tamoxifen - Ovarian Cancer | Phase 2 | Unknown | Sun Yat-sen University | 46 | 2023-01-01 | 2023-01-03 |
| Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer Parimparib, Chemotherapy drug, Targeted Therapy Agent - Carcinoma, Non-Small-Cell Lung, EGF-R Positive Non-Small Cell Lung Cancer | Phase 1 | Unknown | Affiliated Hospital of Jiangnan University | 40 | 2022-12-20 | 2024-01-31 |
| Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer Pamiparib, Surufatinib - Ovarian Cancer | Phase 2 | Recruiting | Bai-Rong Xia | 37 | 2022-11-06 | 2026-10-02 |
| Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer Pamiparib, Surufatinib - Ovarian Cancer, Ovarian Carcinoma | Phase 1 / Phase 2 | Completed | Sun Yat-sen University | 29 | 2022-09-22 | 2026-03-10 |
| A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure Pamiparib - Epithelial Ovarian Cancer | Phase 2 | Unknown | Zhejiang Cancer Hospital | 15 | 2022-08-16 | 2024-01-26 |
| Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer Pamiparib, Bevacizumab, Tislelizumab - Ovarian Cancer | Phase 2 | Completed | Tongji Hospital | 108 | 2022-07-22 | 2025-06-08 |
| Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy Pamiparib - Limited Stage Small Cell Lung Cancer | Phase 2 | Unknown | Fudan University | 44 | 2022-06-20 | 2022-08-02 |
| Pamiparib in mCRPC With HRD or BRCA1/2 Mutation Pamiparib - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Unknown | Sun Yat-sen University | 50 | 2022-05-01 | 2022-04-14 |
| Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer Cisplatin, Gemcitabine, Oxaliplatin - Platinum-Sensitive Biliary Tract Cancer | Phase 2 | Withdrawn | European Organisation for Research and Treatment of Cancer - EORTC | 2022-05-01 | 2022-06-01 | |
| A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects Pamiparib, Tislelizumab - Cancer | Phase 2 | Unknown | Peter MacCallum Cancer Centre, Australia | 60 | 2022-02-24 | 2023-03-15 |
| A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer pamiparib, abiraterone, prednisone - Neoadjuvant Therapy | Phase 2 | Unknown | Hongqian Guo | 30 | 2022-02-22 | 2023-01-05 |
| Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors Cabozantinib, Pamiparib - Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 44 | 2022-02-09 | 2026-05-12 |
| Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer Pamiparib, Temozolomide - Clear Cell Papillary Renal Neoplasm, Collecting Duct Carcinoma | Phase 2 | Withdrawn | Jonsson Comprehensive Cancer Center | 2021-10-18 | 2023-05-17 | |
| Arterial Hypertension Related to PARP Inhibitors (ArteRIB) olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib - Cancer | Completed | University Hospital, Caen | 2336 | 2021-02-24 | 2023-06-06 | |
| Pancytopenia Related to PARP Inhibitors (PancytoRIB) PARP inhibitor - Cancer | Completed | University Hospital, Caen | 200 | 2021-02-07 | 2021-09-23 | |
| Study of Pamiparib in Newly Diagnosed and rGBM Pamiparib, Olaparib, Radiation therapy - Glioblastoma, Glioblastoma Multiforme | Early Phase 1 | Completed | Nader Sanai | 50 | 2021-01-11 | 2026-05-14 |
| BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations PARP Inhibitor BGB-290, Temozolomide, Therapeutic Conventional Surgery - IDH1 Mutation, IDH2 Mutation | Phase 1 / Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 67 | 2020-02-16 | 2025-01-14 |
Showing 20 of 33. Sign in to see all of them.
Ovarian Neoplasms (7) · Glioblastoma (4) · Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (2) · Head and Neck Neoplasms (2) · Stomach Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Astrocytoma (1) · Biliary Tract Neoplasms (1) · Brain Neoplasms (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Carcinosarcoma (1) · Central Nervous System Neoplasms (1) · Esophageal Neoplasms (1)
BeiGene (9) · Sun Yat-sen University (3) · University Hospital, Caen (2) · Affiliated Hospital of Jiangnan University (1) · Australia New Zealand Gynaecological Oncology Group (1) · Bai-Rong Xia (1) · BeOne Medicines (1) · BeiGene USA, Inc. (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Fudan University (1) · Hongqian Guo (1) · Jonsson Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1) · Nader Sanai (1) · Peking University Shenzhen Hospital (1)
China (15) · United States (11) · Australia (8) · France (6) · Spain (4) · Poland (3) · United Kingdom (3) · Georgia (2) · Japan (2) · New Zealand (2) · Taiwan (2) · Belgium (1) · Czechia (1) · Hong Kong (1) · Hungary (1)
Alison Freimund (1) · Ari Rosenberg, MD (1) · Bai-Rong Xia, MD (1) · Brian Shuch, MD (1) · David Schiff, MD (1) · Fangjian Zhou, M.D. (1) · Kaiyan Zhang, M.D. (1) · Michael Millward, MD (1) · Nader Sanai, MD (1) · Qinglei Gao, MD. PhD (1) · Ranjit Bindra, MD (1) · Sabine Mueller, MD, PhD (1) · Siqing Fu (1) · Stephen Luen, MBBS (1)
PMID 31378459, PMID 32652442, PMID 33128299, PMID 33772633, PMID 34795408, PMID 37474720, PMID 38610031, PMID 38658024, PMID 38970256, PMID 40065286
2017 (4), 2019 (2), 2018 (1), 2023 (1), UM1CA137443 (1)